Shanghai Enlemai Biotechnology

Enlemai Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative antibody-based therapeutics for autoimmune diseases and oncology. The company leverages its proprietary antibody engineering platforms to develop a diverse pipeline of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its lead program, ELM-101, is a dual-target antibody targeting IL-17A and IL-17F for the treatment of moderate-to-severe plaque psoriasis and other inflammatory conditions. Enlemai aims to address significant unmet medical needs by optimizing drug efficacy and safety through advanced molecular design.